یکشنبه 15 شهریور 1405
[Archive]
دوره 24، شماره 7 - ( 4-1405 )
جلد 24 شماره 7 صفحات 584-571 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Kiaee F, Shahi H. The lactate-myeloid-derived suppressor cells axis in endometriosis from molecular reprogramming to translational therapies: A review article. IJRM 2026; 24 (7) :571-584
URL: http://ijrm.ir/article-1-3796-fa.html
URL: http://ijrm.ir/article-1-3796-fa.html
محور لاکتات-سلول های سرکوب کننده مشتق از میلویید در اندومتریوز: از برنامهریزی مجدد مولکولی تا درمانهای کاربردی؛ یک مقاله مروری. International Journal of Reproductive BioMedicine. 1405; 24 (7) :571-584
چکیده: (17 مشاهده)
اندومتریوز یک بیماری مزمن پیچیده است که متأثر از هورمون استروژن میباشد و با رشد بافتی شبیه به اندومتر در خارج از رحم مشخص میشود. این بیماری پیچیده، میلیونها زن را در سراسر جهان تحت تأثیر قرار میدهد و به صورت درد شدید لگن، ناباروری قابل توجه و کاهش عمیق کیفیت زندگی آنها بروز میکند. درمان این مشکلات بالینی نیاز به پیشرفت در ابزارهای تشخیصی و استراتژیهای درمانی دارد. این مقاله به بررسی رابطه پیچیده بین اسیدلاکتیک مشتق از اندومتریوز و زیرمجموعه خاصی از سلولهای ایمنی، معروف به سلولهای سرکوبگر مشتق از میلوئید (MDSCs) میپردازد. هدف ما روشن کردن مسیرهای بیولوژیکی ظریفی است که بر این تعامل مهم تأثیر میگذارند. لاکتاتها متعاقباً باعث گسترش و فعال شدن MDSC ها میشوند که سپس سرکوب ایمنی را از طریق مولکولهای سیگنالینگ کلیدی مانند فاکتور القا شده توسط هیپوکسی 1-آلفا، مبدل سیگنال و فعالکننده رونویسی 3، فاکتور هستهای کاپا-زنجیره سبک-تقویتکننده سلولهای B فعال شده افزایش میدهند. فراتر از نقش آن در تعدیل سیستم ایمنی، این تعامل پیچیده بین اسید لاکتیک و MDSCها به عنوان یک عامل محوری در پاتوژنز چندوجهی اندومتریوز می باشد. این امر به طور قابل توجهی در بدتر شدن بیماری، از جمله گسترش تهاجمی آن، ایجاد رگهای خونی جدید (آنژیوژنز) و تشکیل بافت فیبروتیک و اسکار مانند نقش دارد. این فرضیه مروری که تعدیل هدفمند متابولیسم لاکتات میتواند به عنوان یک استراتژی درمانی امیدوارکننده برای تنظیم فعالیت MDSC عمل کند، مطرح شده است. هدف از این مطالعه، روشن کردن این رویدادهای پیچیده سلولی و مولکولی است.
نوع مطالعه: Review article |
فهرست منابع
1. Defrère S, Lousse JC, González-Ramos R, Colette S, Donnez J, Van Langendonckt A. Potential involvement of iron in the pathogenesis of peritoneal endometriosis. Mol Hum Reprod 2008; 14: 377-385. [DOI:10.1093/molehr/gan033] [PMID]
2. Smolarz B, Szyłło K, Romanowicz H. Endometriosis: Epidemiology, classification, pathogenesis, treatment and genetics (review of literature). Int J Mol Sci 2021; 22: 10554. [DOI:10.3390/ijms221910554] [PMID] [PMCID]
3. Symons LK, Miller JE, Kay VR, Marks RM, Liblik K, Koti M, et al. The immunopathophysiology of endometriosis. Trends Mol Med 2018; 24: 748-762. [DOI:10.1016/j.molmed.2018.07.004] [PMID]
4. Vermeulen N, Abrao MS, Einarsson JI, Horne AW, Johnson NP, Lee TTM, et al. Endometriosis classification, staging and reporting systems: A review on the road to a universally accepted endometriosis classification. J Minim Invasive Gynecol 2021; 28: 1822-1848. [DOI:10.1016/j.jmig.2021.07.023] [PMID]
5. Pascoal E, Wessels JM, Aas-Eng MK, Abrao MS, Condous G, Jurkovic D, et al. Strengths and limitations of diagnostic tools for endometriosis and relevance in diagnostic test accuracy research. Ultrasound Obstet Gynecol 2022; 60: 309-327. [DOI:10.1002/uog.24892] [PMID]
6. Rangi S, Hur C, Richards E, Falcone T. Fertility preservation in women with endometriosis. J Clin Med 2023; 12: 4331. [DOI:10.3390/jcm12134331] [PMID] [PMCID]
7. Mavrelos D, Saridogan E. Treatment of endometriosis in women desiring fertility. J Obstet Gynaecol India 2015; 65: 11-16. [DOI:10.1007/s13224-014-0652-y] [PMID] [PMCID]
8. Zhang T, He Y, Man GCW, Ding Y, Wang CC, Chung JPW. Myeloid-derived suppressor cells: A new emerging player in endometriosis. Int Rev Cell Mol Biol 2023; 375: 191-220. [DOI:10.1016/bs.ircmb.2022.11.004] [PMID]
9. Xiong X, Zhang Y, Wen Y. Diverse functions of myeloid-derived suppressor cells in autoimmune diseases. Immunol Res 2024; 72: 34-49. [DOI:10.1007/s12026-023-09421-0] [PMID] [PMCID]
10. Suszczyk D, Skiba W, Jakubowicz-Gil J, Kotarski J, Wertel I. The role of myeloid-derived suppressor cells (MDSCs) in the development and/or progression of endometriosis-state of the Art. Cells 2021; 10: 677. [DOI:10.3390/cells10030677] [PMID] [PMCID]
11. Zhang T, Zhou J, Man GCW, Leung KT, Liang B, Xiao B, et al. MDSCs drive the process of endometriosis by enhancing angiogenesis and are a new potential therapeutic target. Eur J Immunol 2018; 48: 1059-1073. [DOI:10.1002/eji.201747417] [PMID] [PMCID]
12. Gou Y, Wang H, Wang T, Wang B, Jiao N, Yu Y, et al. Ectopic endometriotic stromal cells-derived lactate induces M2 macrophage polarization via Mettl3/Trib1/ERK/STAT3 signalling pathway in endometriosis. Immunology 2023; 168: 389-402. [DOI:10.1111/imm.13574] [PMID]
13. Kobayashi H, Shigetomi H, Imanaka S. Nonhormonal therapy for endometriosis based on energy metabolism regulation. Reprod Fertil 2021; 2: C42-C57. [DOI:10.1530/RAF-21-0053] [PMID] [PMCID]
14. Young VJ, Brown JK, Maybin J, Saunders PT, Duncan WC, Horne AW. Transforming growth factor-β induced Warburg-like metabolic reprogramming may underpin the development of peritoneal endometriosis. J Clin Endocrinol Metab 2014; 99: 3450-3459. [DOI:10.1210/jc.2014-1026] [PMID] [PMCID]
15. Zhang Y, Zhai Z, Duan J, Wang X, Zhong J, Wu L, et al. Lactate: The mediator of metabolism and immunosuppression. Front Endocrinol 2022; 13: 901495. [DOI:10.3389/fendo.2022.901495] [PMID] [PMCID]
16. Gantt S, Gervassi A, Jaspan H, Horton H. The role of myeloid-derived suppressor cells in immune ontogeny. Front Immunol 2014; 5: 387. [DOI:10.3389/fimmu.2014.00387] [PMID] [PMCID]
17. Ge Y, Cheng D, Jia Q, Xiong H, Zhang J. Mechanisms underlying the role of myeloid-derived suppressor cells in clinical diseases: Good or bad. Immune Netw 2021; 21: e21. [DOI:10.4110/in.2021.21.e21] [PMID] [PMCID]
18. Salminen A, Kauppinen A, Kaarniranta K. Myeloid-derived suppressor cells (MDSC): An important partner in cellular/tissue senescence. Biogerontology 2018; 19: 325-339. [DOI:10.1007/s10522-018-9762-8] [PMID]
19. Xu D, Li C, Xu Y, Huang M, Cui D, Xie J. Myeloid-derived suppressor cell: A crucial player in autoimmune diseases. Front Immunol 2022; 13: 1021612. [DOI:10.3389/fimmu.2022.1021612] [PMID] [PMCID]
20. He Y, Liang B, Hung SW, Zhang R, Xu H, Chung JPW, et al. Re-evaluation of mouse models of endometriosis for pathological and immunological research. Front Immunol 2022; 13: 986202. [DOI:10.3389/fimmu.2022.986202] [PMID] [PMCID]
21. Grover A, Sanseviero E, Timosenko E, Gabrilovich DI. Myeloid-derived suppressor cells: A propitious road to clinic. Cancer Discov 2021; 11: 2693-2706. [DOI:10.1158/2159-8290.CD-21-0764] [PMID]
22. He Y, Hung SW, Liang B, Zhang R, Gao Y, Chu CY, et al. Receptor tyrosine kinase inhibitor sunitinib as novel immunotherapy to inhibit myeloid-derived suppressor cells for treatment of endometriosis. Front Immunol 2021; 12: 641206. [DOI:10.3389/fimmu.2021.641206] [PMID]
23. Li X, Yang Y, Zhang B, Lin X, Fu X, An Y, et al. Lactate metabolism in human health and disease. Signal Transduct Target Ther 2022; 7: 305. [DOI:10.1038/s41392-022-01151-3] [PMID]
24. Melkonian EA, Schury MP. Biochemistry, anaerobic glycolysis. StatPearls. Treasure Island FL ineligible companies. Disclosure: Mark schury declares no relevant financial relationships with ineligible companies. StatPearls Publishing LLC.; 2024.
25. Zheng J, Dai Y, Lin X, Huang Q, Shi L, Jin X, et al. Hypoxia induced lactate dehydrogenase A protects cells from apoptosis in endometriosis. Mol Med Rep 2021; 24: 637. [DOI:10.3892/mmr.2021.12276] [PMID] [PMCID]
26. Horne AW, Missmer SA. Pathophysiology, diagnosis, and management of endometriosis. BMJ 2022; 379: e070750. [DOI:10.1136/bmj-2022-070750] [PMID]
27. Zhou WJ, Yang HL, Shao J, Mei J, Chang KK, Zhu R, et al. Anti-inflammatory cytokines in endometriosis. Cell Mol Life Sci 2019; 76: 2111-2132. [DOI:10.1007/s00018-019-03056-x] [PMID] [PMCID]
28. Hashimoto Y, Tsuzuki-Nakao T, Kida N, Matsuo Y, Maruyama T, Okada H, et al. Inflammatory cytokine-induced HIF-1 activation promotes epithelial-mesenchymal transition in endometrial epithelial cells. Biomedicines 2023; 11: 210. [DOI:10.3390/biomedicines11010210] [PMID] [PMCID]
29. Thézénas ML, De Leo B, Laux-Biehlmann A, Bafligil C, Elger B, Tapmeier T, et al. Amine oxidase 3 is a novel pro-inflammatory marker of oxidative stress in peritoneal endometriosis lesions. Sci Rep 2020; 10: 1495.
https://doi.org/10.1038/s41598-020-62492-z [DOI:10.1038/s41598-020-58362-3]
30. Ghanbari Movahed Z, Rastegari-Pouyani M, Mohammadi MH, Mansouri K. Cancer cells change their glucose metabolism to overcome increased ROS: One step from cancer cell to cancer stem cell? Biomed Pharmacother 2019; 112: 108690. [DOI:10.1016/j.biopha.2019.108690] [PMID]
31. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008; 8: 425-437.
https://doi.org/10.1038/nrc2397 [DOI:10.1038/nrc2438] [PMID] [PMCID]
32. Frangogiannis NG. Chemokines in ischemia and reperfusion. Thromb Haemos 2007; 97: 738-747. [DOI:10.1160/TH07-01-0022]
33. Lai ZZ, Yang HL, Ha SY, Chang KK, Mei J, Zhou WJ, et al. Cyclooxygenase-2 in endometriosis. Int J Biol Sci 2019; 15: 2783-2797. [DOI:10.7150/ijbs.35128] [PMID] [PMCID]
34. Yu K, Huang ZY, Xu XL, Li J, Fu XW, Deng SL. Estrogen receptor function: Impact on the human endometrium. Front Endocrinol 2022; 13: 827724. [DOI:10.3389/fendo.2022.827724] [PMID] [PMCID]
35. Mori T, Ito F, Koshiba A, Kataoka H, Takaoka O, Okimura H, et al. Local estrogen formation and its regulation in endometriosis. Reprod Med Biol 2019; 18: 305-311. [DOI:10.1002/rmb2.12285] [PMID] [PMCID]
36. Wang Y, Xiu J, Yang T, Ren C, Yu Z. HSF1 promotes endometriosis development and glycolysis by up-regulating PFKFB3 expression. Reprod Biol Endocrinol 2021; 19: 86. [DOI:10.1186/s12958-021-00770-9] [PMID] [PMCID]
37. Iwanaga T, Kishimoto A. Cellular distributions of monocarboxylate transporters: A review. Biomed Res 2015; 36: 279-301. [DOI:10.2220/biomedres.36.279] [PMID]
38. Halestrap AP. The monocarboxylate transporter family: Structure and functional characterization. IUBMB Life 2012; 64: 1-9.
https://doi.org/10.1002/iub.572 [DOI:10.1002/iub.573]
39. Infantino V, Santarsiero A, Convertini P, Todisco S, Iacobazzi V. Cancer cell metabolism in hypoxia: Role of HIF-1 as key regulator and therapeutic target. Int J Mol Sci 2021; 22: 5703. [DOI:10.3390/ijms22115703] [PMID]
40. Payen VL, Mina E, Van Hée VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Mol Metab 2020; 33: 48-66. [DOI:10.1016/j.molmet.2019.07.006] [PMID] [PMCID]
41. Garcia Garcia JM, Vannuzzi V, Donati C, Bernacchioni C, Bruni P, Petraglia F. Endometriosis: Cellular and molecular mechanisms leading to fibrosis. Reprod Sci 2023; 30: 1453-1461. [DOI:10.1007/s43032-022-01083-x] [PMID] [PMCID]
42. Latif A, Chadwick AL, Kitson SJ, Gregson HJ, Sivalingam VN, Bolton J, et al. Monocarboxylate transporter 1 (MCT1) is an independent prognostic biomarker in endometrial cancer. BMC Clin Pathol 2017; 17: 27. [DOI:10.1186/s12907-017-0067-7] [PMID] [PMCID]
43. Wang ZH, Peng WB, Zhang P, Yang XP, Zhou Q. Lactate in the tumour microenvironment: From immune modulation to therapy. EBioMed 2021; 73: 103627. [DOI:10.1016/j.ebiom.2021.103627] [PMID]
44. Husain Z, Huang Y, Seth P, Sukhatme VP. Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells. J Immunol 2013; 191: 1486-1495. [DOI:10.4049/jimmunol.1202702] [PMID] [PMCID]
45. Cai TT, Ye SB, Liu YN, He J, Chen QY, Mai HQ, et al. LMP1-mediated glycolysis induces myeloid-derived suppressor cell expansion in nasopharyngeal carcinoma. PLoS Pathogen 2017; 13: e1006503. [DOI:10.1371/journal.ppat.1006503] [PMID] [PMCID]
46. Horne AW, Ahmad SF, Carter R, Simitsidellis I, Greaves E, Hogg C, et al. Repurposing dichloroacetate for the treatment of women with endometriosis. Proc Natl Acad Sci U S A 2019; 116: 25389-25391. [DOI:10.1073/pnas.1916144116] [PMID] [PMCID]
47. Feng X, Wang P, Liu Q, Zhang T, Mai B, Wang X. Glycolytic inhibitors 2-deoxyglucose and 3-bromopyruvate synergize with photodynamic therapy respectively to inhibit cell migration. J Bioenerg Biomembr 2015; 47: 189-197. [DOI:10.1007/s10863-015-9604-1] [PMID]
48. Pajak B, Siwiak E, Sołtyka M, Priebe A, Zieliński R, Fokt I, et al. 2-deoxy-d-glucose and its analogs: From diagnostic to therapeutic agents. Int J Mol Sci 2019; 21: 234. [DOI:10.3390/ijms21010234] [PMID]
49. Leow HW, Koscielniak M, Williams L, Saunders PTK, Daniels J, Doust AM, et al. Dichloroacetate as a possible treatment for endometriosis-associated pain: A single-arm open-label exploratory clinical trial (EPiC). Pilot Feasibil Stud 2021; 7: 67. [DOI:10.1186/s40814-021-00797-0] [PMID] [PMCID]
50. Benjamin D, Robay D, Hindupur SK, Pohlmann J, Colombi M, El-Shemerly MY, et al. Dual inhibition of the lactate transporters MCT1 and MCT4 is synthetic lethal with metformin due to NAD+ depletion in cancer cells. Cell Rep 2018; 25: 3047-3058. [DOI:10.1016/j.celrep.2018.11.043] [PMID] [PMCID]
51. van der Mijn JC, Panka DJ, Geissler AK, Verheul HM, Mier JW. Novel drugs that target the metabolic reprogramming in renal cell cancer. Cancer Metab 2016; 4: 14. [DOI:10.1186/s40170-016-0154-8] [PMID] [PMCID]
52. Han JH, Lee EJ, Park W, Ha KT, Chung HS. Natural compounds as lactate dehydrogenase inhibitors: Potential therapeutics for lactate dehydrogenase inhibitors-related diseases. Front Pharmacol 2023; 14: 1275000. [DOI:10.3389/fphar.2023.1275000] [PMID] [PMCID]
53. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 2010; 17: 672-697. [DOI:10.2174/092986710790416263] [PMID]
54. Miean KH, Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. J Agricult Food Chem 2001; 49: 3106-3112. [DOI:10.1021/jf000892m] [PMID]
55. Cho MK, Jin L, Han JH, Jin JS, Cheon SY, Shin S, et al. Water-extracted prunella vulgaris alleviates endometriosis by reducing aerobic glycolysis. Front Pharmacol 2022; 13: 872810.
https://doi.org/10.3389/fphar.2022.1112004 [DOI:10.3389/fphar.2022.872810]
56. Huang WY, Cai YZ, Zhang Y. Natural phenolic compounds from medicinal herbs and dietary plants: Potential use for cancer prevention. Nutr Cancer 2010; 62: 1-20. [DOI:10.1080/01635580903191585] [PMID]
57. Kooshki L, Mahdavi P, Fakhri S, Akkol EK, Khan H. Targeting lactate metabolism and glycolytic pathways in the tumor microenvironment by natural products: A promising strategy in combating cancer. BioFactors 2022; 48: 359-383. [DOI:10.1002/biof.1799] [PMID]
58. Kozal K, Jóźwiak P, Krześlak A. Contemporary perspectives on the Warburg effect inhibition in cancer therapy. Cancer Control 2021; 28: 10732748211041243. [DOI:10.1177/10732748211041243] [PMID] [PMCID]
59. Fiume L, Vettraino M, Carnicelli D, Arfilli V, Di Stefano G, Brigotti M. Galloflavin prevents the binding of lactate dehydrogenase A to single stranded DNA and inhibits RNA synthesis in cultured cells. Biochem Biophys Res Commun 2013; 430: 466-469. [DOI:10.1016/j.bbrc.2012.12.013] [PMID]
60. Han X, Sheng X, Jones HM, Jackson AL, Kilgore J, Stine JE, et al. Evaluation of the anti-tumor effects of lactate dehydrogenase inhibitor galloflavin in endometrial cancer cells. J Hematol Oncol 2015; 8: 2. [DOI:10.1186/s13045-014-0097-x] [PMID] [PMCID]
61. Makker V, Colombo N, Casado Herráez A, Monk BJ, Mackay H, Santin AD, et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775. J Clin Oncol 2023; 41: 2904-2910.
https://doi.org/10.1200/JCO.22.01021 [DOI:10.1200/JCO.22.02152]
62. Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun 2018; 9: 1685. [DOI:10.1038/s41467-018-03966-7] [PMID] [PMCID]
63. Grisham RN, Adaniel C, Hyman DM, Ma W, Iasonos A, Aghajanian C, et al. Gemcitabine for advanced endometrial cancer: A retrospective study of the memorial sloan-kettering cancer center experience. Int J Gynecol Cancer 2012; 22: 807-811. [DOI:10.1097/IGC.0b013e31824a33a2] [PMID] [PMCID]
64. Zhao JL, Ye YC, Gao CC, Wang L, Ren KX, Jiang R, et al. Notch-mediated lactate metabolism regulates MDSC development through the Hes1/MCT2/c-Jun axis. Cell Rep 2022; 38: 110451. [DOI:10.1016/j.celrep.2022.110451] [PMID]
65. Yang X, Lu Y, Hang J, Zhang J, Zhang T, Huo Y, et al. Lactate-modulated immunosuppression of myeloid-derived suppressor cells contributes to the radioresistance of pancreatic cancer. Cancer Immunol Res 2020; 8: 1440-1451. [DOI:10.1158/2326-6066.CIR-20-0111] [PMID]
66. Quiroga J, Alarcón P, Manosalva C, Teuber S, Taubert A, Hermosilla C, et al. Metabolic reprogramming and inflammatory response induced by D-lactate in bovine fibroblast-like synoviocytes depends on HIF-1 activity. Front Vet Sci 2021; 8: 625347. [DOI:10.3389/fvets.2021.625347] [PMID] [PMCID]
67. Tengesdal IW, Dinarello A, Powers NE, Burchill MA, Joosten LAB, Marchetti C, et al. Tumor NLRP3-derived IL-1β drives the IL-6/STAT3 axis resulting in sustained MDSC-mediated immunosuppression. Front Immunol 2021; 12: 661323. [DOI:10.3389/fimmu.2021.661323] [PMID] [PMCID]
68. Weber R, Groth C, Lasser S, Arkhypov I, Petrova V, Altevogt P, et al. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cell Immunol 2021; 359: 104254. [DOI:10.1016/j.cellimm.2020.104254] [PMID]
69. Bruno A, Mortara L, Baci D, Noonan DM, Albini A. Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: Roles in tumor progression. Front Immunol 2019; 10: 771. [DOI:10.3389/fimmu.2019.00771] [PMID] [PMCID]
70. Long L, Xiong W, Lin F, Hou J, Chen G, Peng T, et al. Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery. J Exp Clin Cancer Res 2023; 42: 117. [DOI:10.1186/s13046-023-02688-z] [PMID] [PMCID]
71. Kiaee F, Jamaati H, Shahi H, Dalil Roofchayee N, Varahram M, Folkerts G, et al. Immunophenotype and function of circulating myeloid derived suppressor cells in COVID-19 patients. Sci Rep 2022; 12: 22570. [DOI:10.1038/s41598-022-26943-z] [PMID] [PMCID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
